Lupin Shares Surge as USFDA Approves Dapagliflozin and Metformin Tablets
Lupin shares to be in focus on Thursday as USFDA approves Dapagliflozin and Metformin tablets
Mint
Image: Mint
Lupin's shares are set to attract investor attention following the U.S. FDA's approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets. The approval, part of Lupin's strategy to expand its specialty care portfolio, comes as the company also completes its acquisition of VISUfarma, enhancing its presence in the European ophthalmology market.
- 01Lupin received U.S. FDA approval for Dapagliflozin and Metformin tablets.
- 02The approved tablets are bioequivalent to Xigduo XR.
- 03Lupin completed the acquisition of VISUfarma B.V. to enhance its specialty care portfolio.
- 04The company's shares have gained 22% over the past six months.
- 05Lupin's stock performance was negative in 2025, with a decline of 10.45%.
Advertisement
In-Article Ad
Lupin Pharmaceuticals has gained significant attention as it announced the U.S. FDA's approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets. This approval, part of its Abbreviated New Drug Application (ANDA), covers various strengths and positions Lupin to compete with Xigduo XR. Additionally, the company has completed its acquisition of VISUfarma B.V., a European specialty pharmaceutical firm focused on ophthalmology, enhancing its capabilities to meet the growing demand for eye care solutions. Despite a 22% gain over the last six months, Lupin's stock experienced a 10.45% decline in 2025, following two years of positive returns. Investors are advised to consult with experts before making investment decisions.
Advertisement
In-Article Ad
The FDA approval may lead to increased sales for Lupin, potentially affecting stock prices and investor confidence.
Advertisement
In-Article Ad
Reader Poll
Do you think Lupin's acquisition of VISUfarma will positively impact its market position?
Connecting to poll...
Read the original article
Visit the source for the complete story.